The IMF trims its economic growth forecast again as the U.S.-China trade war continues, Brexit worries linger and inflation remains muted.Economyread more
Citigroup thinks Tesla investors hoping for a post-earnings rally later this week should scrutinize a pair of related financial metrics.Investingread more
Olive branches were extended from both China and the U.S. as the two nations are set to restart face-to-face trade negotiations after a monthlong truce.Marketsread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
New disclosures show Facebook and Amazon each spent more than $4 million on lobbying activity in the second quarter of 2019.Technologyread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
Disney can nearly double its earnings by 2024, Morgan Stanley said in a note to clients on Tuesday.Investingread more
Amazon is expected to report its second-quarter earnings on Thursday.Investingread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Canaccord Genuity's Tony Dwyer believes stocks are about to fall as much as 5% from their all-time highs.Trading Nationread more
Pershing Square raised its holdings by 14,644,618 shares to 34,118,551 — meaning a total stake of about 9.9 percent from 5.68 percent. Pershing was already one of the largest holders of Valeant stock.
The fund revealed its new holdings in an updated Schedule 13D filing with the U.S. Securities and Exchange Commission, and announced the move in a Monday afternoon news release.
Shares in the company jumped more than 2 percent in after-hours trading.
This comes after Ackman told CNBC on October 21 that he had purchased an additional 2 million shares of Valeant as the stock plunged on an explosive note from Citron Research that alleged the drugmaker is channel stuffing.
Ackman told CNBC at the time that he still believed in the company despite Citron claims.
Read More Bill Ackman: I believe in Valeant
Citron alleged that Valeant is using a network of specialty mail-order pharmacies that the company actually controls to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generics. The report went so far as to call Valeant the "pharmaceutical Enron."
Since that report, Valeant has seen significant turmoil, forcing the company to to retain staff.
Valeant's stock has fallen about 60 percent over the last three months.